AstraZeneca contemplating a $15B licensing deal for Summit's Keytruda killer, ivonescimab. Hmmm.... makes you wonder how much Merck would pay us so they can combine leronlimab with Keytruda and fight off ivonescimab.
https://pharmaphorum.com/news/summit-climbs-r...a-interest